Overview on Juvenile Idiopathic Arthritis: A Review
-
Published:2021-08-10
Issue:
Volume:
Page:139-147
-
ISSN:2456-9119
-
Container-title:Journal of Pharmaceutical Research International
-
language:
-
Short-container-title:JPRI
Author:
Hazazi Ahlam Shary J.,Alshehri Badaya Awadh M.,Alali Yara Abdulrahman,Alqarni Rahf Mohammed I.,Hazazi Ibtisam Shary J.,Albalawi Nujud Abdulqader,Murad Dimah Mohammed A. Abu,Alatawi Atheer Mansour E,Alatawi Nouf Ali,Yousuf Maisaa Mokhtar M.
Abstract
Juvenile idiopathic arthritis (JIA) is a broad term that refers to a clinically heterogeneous group of arthritis that develops before the age of 16 and has no recognized cause. JIA treatment has evolved during the last two decades. Clinical trials research has been directed at more specific therapeutics based on what has been discovered about the biology of disease. Pediatric rheumatologists now have many more medications to offer patients, with the expectation that their disease will be managed, thanks to advances in immune system research and the introduction of biologic drugs in the twenty-first century. Continuing development in these biological agents and discoveries new drugs as long as developing current gene analysis techniques is the best method to treat JIA and provide best quality of life.
Publisher
Sciencedomain International